透明质酸间隔物在前列腺癌放疗中的剂量学效应、间隔物稳定性及长期毒性与患者报告结局:一项II期研究
这项II期研究纳入81例低危和中危前列腺癌患者,在外照射放疗(78 Gy/39次)前经直肠注射透明质酸间隔物。MRI显示间隔物显著降低直肠V70%和V90%,但间隔物厚度和CTV-直肠间隙在放疗中后期缩小;5年累积晚期≥2级胃肠道毒性为5%,泌尿生殖毒性为12%。
要点
- 透明质酸间隔物注射后直肠V70%和V90%显著降低,但放疗中后期间隔物厚度和CTV-直肠间隙缩小。
- 5年累积晚期≥2级胃肠道毒性和泌尿生殖毒性分别为5%和12%。
- 5年随访时患者报告中度或重度整体肠道问题和泌尿问题分别为12%和10%。
核心结论
- 透明质酸间隔物降低了直肠剂量和长期毒性。
研究设计与样本
- II期研究,纳入81例低危和中危前列腺癌患者,在外照射放疗(78 Gy/39次)前经直肠注射透明质酸间隔物。
- 用MRI在注射前(MR0)、注射后(MR1)、放疗中期(MR2)和放疗结束时(MR3)共评估间隔物四次。
- 由医生根据RTOG量表评估胃肠道和泌尿生殖毒性长达5年,并使用瑞典国家前列腺癌登记处和前列腺癌症状量表问卷收集患者报告结局。
主要发现
- MR0与MR1之间以及MR0与MR2、MR3之间,直肠V70%(54.6 Gy)和V90%(70.2 Gy)显著降低。
- 从MR1到MR2/MR3,中间层面的透明质酸厚度减少28%/32%,CTV-直肠间隙减少19%/17%。
- 5年累积晚期≥2级胃肠道毒性为5%,5年随访时患者报告中度或重度整体肠道问题比例为12%。
- 5年累积晚期≥2级泌尿生殖毒性为12%,5年时中度或重度整体泌尿问题为10%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Perirectal spacers may be beneficial to reduce rectal side effects from radiotherapy (RT). Here, we present the impact of a hyaluronic acid (HA) perirectal spacer on rectal dose as well as spacer stability, long-term gastrointestinal (GI) and genitourinary (GU) toxicity and patient-reported outcome (PRO). METHODS: In this phase II study 81 patients with low- and intermediate-risk prostate cancer received transrectal injections with HA before external beam RT (78 Gy in 39 fractions). The HA spacer was evaluated with MRI four times; before (MR0) and after HA-injection (MR1), at the middle (MR2) and at the end (MR3) of RT. GI and GU toxicity was assessed by physician for up to five years according to the RTOG scale. PROs were collected using the Swedish National Prostate Cancer Registry and Prostate cancer symptom scale questionnaires. RESULTS: There was a significant reduction in rectal V70% (54.6 Gy) and V90% (70.2 Gy) between MR0 and MR1, as well as between MR0 to MR2 and MR3. From MR1 to MR2/MR3, HA thickness decreased with 28%/32% and CTV-rectum space with 19%/17% in the middle level. The cumulative late grade ≥ 2 GI toxicity at 5 years was 5% and the proportion of PRO moderate or severe overall bowel problems at 5 years follow-up was 12%. Cumulative late grade ≥ 2 GU toxicity at 5 years was 12% and moderate or severe overall urinary problems at 5 years were 10%. CONCLUSION: We show that the HA spacer reduced rectal dose and long-term toxicity.
引用
- Björeland U, Notstam K, Fransson P, et al. Hyaluronic acid spacer in prostate cancer radiotherapy: dosimetric effects, spacer stability and long-term toxicity and PRO in a phase II study. Radiat Oncol. 2023. PMID: 36593460. doi:10.1186/s13014-022-02197-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。